open access

Vol 16, No 4 (2020)
Review paper
Published online: 2020-08-17
Get Citation

Neratinib in extended adjuvant therapy for HER2-positive early breast cancer

Tomasz Kubiatowski
DOI: 10.5603/OCP.2020.0013
·
Oncol Clin Pract 2020;16(4):201-205.

open access

Vol 16, No 4 (2020)
REVIEW ARTICLES
Published online: 2020-08-17

Abstract

HER2 overexpression is found in approximately 20% of patients with breast cancer and is associated with an unfavorable prognosis. The use of chemotherapy and targeted therapies blocking HER2 function in patients with early HER2 positive breast cancer has led to significant clinical benefits. Despite this, approximately 25% of patients initially treated with trastuzumab experience recurrence of invasive disease within 5 years of completion of adjuvant treatment. Neratinib is an oral, irreversible, small molecule tyrosine kinase inhibitor blocking the intracellular domain of the HER1, HER2 and HER4 receptor, whose activity in extended anti-HER2 adjuvant treatment in HER2-positive early breast cancer patients has been confirmed in ExteNET trial. It has been shown that the use of extended therapy with neratinib after adjuvant trastuzumab treatment in patients with early HER2-positive breast cancer led to a 33% reduction in the risk of invasive disease recurring, with a greater effect observed in ER/PgR positive patients and those with involvement 4 and more lymph nodes.

Abstract

HER2 overexpression is found in approximately 20% of patients with breast cancer and is associated with an unfavorable prognosis. The use of chemotherapy and targeted therapies blocking HER2 function in patients with early HER2 positive breast cancer has led to significant clinical benefits. Despite this, approximately 25% of patients initially treated with trastuzumab experience recurrence of invasive disease within 5 years of completion of adjuvant treatment. Neratinib is an oral, irreversible, small molecule tyrosine kinase inhibitor blocking the intracellular domain of the HER1, HER2 and HER4 receptor, whose activity in extended anti-HER2 adjuvant treatment in HER2-positive early breast cancer patients has been confirmed in ExteNET trial. It has been shown that the use of extended therapy with neratinib after adjuvant trastuzumab treatment in patients with early HER2-positive breast cancer led to a 33% reduction in the risk of invasive disease recurring, with a greater effect observed in ER/PgR positive patients and those with involvement 4 and more lymph nodes.

Get Citation

Keywords

neratinib, extended adjuvant treatment, HER2-positive early breast cancer

About this article
Title

Neratinib in extended adjuvant therapy for HER2-positive early breast cancer

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 4 (2020)

Article type

Review paper

Pages

201-205

Published online

2020-08-17

DOI

10.5603/OCP.2020.0013

Bibliographic record

Oncol Clin Pract 2020;16(4):201-205.

Keywords

neratinib
extended adjuvant treatment
HER2-positive early breast cancer

Authors

Tomasz Kubiatowski

References (22)
  1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785): 177–182.
  2. Lambertini M, Pondé NF, Solinas C, et al. Adjuvant trastuzumab: a 10-year overview of its benefit. Expert Rev Anticancer Ther. 2017; 17(1): 61–74.
  3. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017; 389(10075): 1195–1205.
  4. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016; 34(10): 1034–1042.
  5. Slamon DL, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2¬positive, node¬positive, or high¬risk node¬negative breast cancer. Cancer Res 2013; 73 (suppl 24): S1–03 (abstr).
  6. von Minckwitz G, Procter M, de Azambuja E, et al. APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017; 377(2): 122–131.
  7. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010; 28(8): 1301–1307.
  8. Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009; 15(7): 2552–2558.
  9. Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim). 2008; 341(8): 465–477.
  10. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004; 64(11): 3958–3965.
  11. Zhang Y, Zhang J, Liu C, et al. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 2016; 382(2): 176–185.
  12. Martin M, Bonneterre J, Geyer CE, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013; 49(18): 3763–3772.
  13. Chan A, Delaloge S, Holmes F, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2016; 17(3): 367–377.
  14. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32(33): 3744–3752.
  15. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011; 29(34): 4491–4497.
  16. Slamon D, Eiermann W, Robert N, et al. BCIRG 006 Phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. 2009.
  17. Dhillon S, Dhillon S, Dhillon S. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU. Clin Drug Investig. 2019; 39(2): 221–229.
  18. Gnant M, Martin M, Holmes FA, et al. Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early stage breast cancer: subgroup analyses from the phase III ExteNET trial. Presented at the 41st San Antonio Breast Cancer Symposium, Dec 4-8, 2018, San Antonio, Tx, USA.
  19. Martin M, Holmes FA, Ejlertsen B, et al. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(12): 1688–1700.
  20. Giuliano M, Trivedi MV, Schiff R. Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. Breast Care (Basel). 2013; 8(4): 256–262.
  21. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(8): 1194–1220.
  22. www.nice.org.uk/guidance/ta612.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl